Tau phosphorylation is decreased in neurons treated with 20 mM KCl. by Nguyen-Vi Mohamed (323606)

“…<p>Immunoblot analysis of Tau phosphorylation in neurons treated either with 10mM or 20mM KCl. The phosphorylation of S199/S202, T181, T205 and S404 was not significantly affected by 10mM of KCl treatment whereas the phosphorylation of all these sites was decreased by 20mM of KCl treatment. …”

Increasing temperature decreases oxygen concentration and decreasing oxygen content decreases neuronal excitability. by Yuguo Yu (172221)

MVEC viability is decreased over time in PEG-based hydrogels. by Rebecca A. Scott (488956)

MMP-2 production is decreased following ALK5 inhibition. by Rebecca A. Scott (488956)

MSCs decrease lung inflammation. by Konrad Urbanek (439073)

Summary of decrease in VASD categorised by response on Likert scale. by Eleanor K. Mishra (724106)

Genes whose expression was decreased by 1 mM ouabain by more than 2-fold. by Larisa V. Smolyaninova (3600053)

Metformin decreases ATP levels in medium containing low glucose (2.5 mM). by Yongxian Zhuang (634693)

TQ decreases CXCR4 expression on MM cells and CXCL12-induced CXCR4/CD45 association. by Gamal Badr (113166)

Subjects:

Sodium taurocholate decreased higher order oligomerization. by Eunhee Lee (804130)

Treatment with ICG-001 decreases viability and induces growth arrest of MM cells. by Eileen R. Grigson (687940)

Prolonged telomerase inhibition decreases MM CSC telomere length and clonogenic potential. by Sarah K. Brennan (362021)

shRNA mediated silencing of CDK9 decreased proliferation of MM cells. by Su-Lin Lim (8997650)

A New Rotane Family:  Synthesis, Structure, Conformation, and Dynamics of [3.4]-, [4.4]-, [5.4]-, and [6.4]Rotane¹ by Lutz Fitjer (2466634)

“…All syntheses are based on bicyclobutylidene (<b>9</b>):  [2+1] cycloaddition of cyclobutylidene yields [3.4]rotane (<b>5</b>) (<b>9</b>−<b>5</b>), [2+2] cycloaddition of trimethyleneketene followed by spiroalkylation of the resulting trispiroketone <b>10</b> yields [4.4]rotane (<b>6</b>) (<b>9</b>−<b>10</b>−<b>13</b>−<b>14</b>−<b>6</b>), homologization of <b>10</b> via β-hydroxy selenides gives access to tetraspiroketone <b>11</b> and pentaspiroketone <b>12</b> (<b>10</b>−<b>15</b>−<b>11</b>−<b>16</b>−<b>12</b>), and further elaboration directed toward a cyclopropylcarbene−cyclobutene rearrangement yields [5.4]rotane (<b>7</b>) and [6.4]rotane (<b>8</b>) [<b>11</b>(<b>12</b>)−<b>18</b>(<b>24</b>)−<b>19</b>(<b>25</b>)−<b>20</b>(<b>26</b>)−<b>21</b>(<b>27</b>)−<b>22</b>(<b>28</b>)−<b>23</b>(<b>29</b>)−<b>7</b>(<b>8</b>)]. …”

Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

Decreased immunoreactivity of AQP4 in LBP-treated brain. by Di Yang (126672)

“…<p>(A–C) AQP4 IHC signals in swollen end-feet of astrocytes around cerebral vessels in ipsilateral penumbral areas (interaural 1.98 mm). …”

eNOS phosphorylation increased intracellular ROS generation and decreased cell viability in BH4-depleted cells. by Hu Peng (396074)

“…<p>(A) HEK 293 cells were treated with DMSO or 10mM DAHP for 24 hours to deplete BH4, then transfected with either control vector or WT eNOS plasmid DNA overnight. …”

Capillary density–decreased capillary density in HCM patients. by Louise L. A. M. Nijenkamp (8805293)

“…<p>A) Representative CD31 staining of HCM stage II and IV samples are shown. B) Capillary density is depicted as the number of capillaries per mm². …”

Inhibition of the mitochondrial fission decreases mtROS production. by Dong Ma (584680)

LNT decreases the pathological changes of lymphedema. by Jung-Ju Huang (604432)